Thermo Fisher Launches Hand Eczema Patient Registry Copy

Thermo Fisher Scientific has launched the PPD CorEvitas Chronic Hand Eczema Registry, a prospective observational cohort study designed to generate real-world evidence on patients being treated for chronic hand eczema in routine clinical care. Announced on 8 June 2026 from Waltham, Massachusetts, the registry is now open to enrolment in North America and will track treatment patterns, disease burden and long-term outcomes for both established and emerging therapies.

The registry collects clinician-reported outcomes such as IGA-CHE and HECSI scores, alongside patient-reported outcomes including HEIS, DLQI, WPAI, DermSat-7, worst skin pain and peak itch. A distinctive design feature is the capture of patient-reported symptoms, treatment experience, quality of life and work productivity at 7 and 30 days after a new drug is initiated, providing structured visibility on perceived rapid response and early tolerability. Longitudinal data covering disease history, comorbidities and treatment patterns will sit alongside outcome measures throughout enrolment.

Chronic hand eczema is an inflammatory skin condition characterised by persistent hand dermatitis lasting more than three months or recurring at least twice a year, and is the most common occupational skin disease among workers exposed to wet work, including healthcare workers, food handlers and hairdressers. Physician-diagnosed prevalence sits at 9.6% of US adults, with significant impact on daily activities and earning capacity. Dr Peter Wahl, vice president and global head of scientific affairs at PPD CorEvitas Clinical Registries, said the registry will support biopharma and biotech sponsors, clinicians and researchers with regulatory-grade longitudinal data as new therapies enter the category.

The CorEvitas franchise has become one of the more strategically useful pieces of Thermo Fisher’s PPD acquisition, plugging directly into the rising regulator and payer demand for real-world evidence alongside randomised trial data. With multiple novel chronic hand eczema therapies in development from the major dermatology players, this registry positions Thermo Fisher to serve as the structured data backbone for the category.